Zusammenfassung
Epidemiologische Studien bei schizophrenen Patienten zeigen ein Lebenszeitrisiko von 20 – 50 % für eine komorbide Suchtstörung. Bei Patienten mit einer ersten Episode liegt die Prävalenz für eine komorbide Suchterkrankung zwischen 25 – 75 %, vor allem Cannabisgebrauch. Diese schwierig zu behandelnde Patientengruppe hat meist einen schlechteren Verlauf als schizophrene Patienten, die keine komorbide Suchtstörung aufweisen. Trotz zahlreicher Erklärungsmodelle, wie der Selbstmedikationshypothese, allgemeinen oder bidirektionalen Faktorenmodellen oder genetischer Vulnerabilität, kann keines umfassend die hohe Suchtkomorbidität bei schizophrenen Patienten erklären, wobei dies wichtig wäre, um diese Gruppe besser behandeln zu können. Da die Gruppe der Doppeldiagnosepatienten sehr heterogen ist, ist es möglich, dass verschiedene Erklärungsmodelle die Komorbidität in verschiedenen Subgruppen erklären könnten. Der vorliegende erste Teil der Übersichtsarbeit „Doppeldiagnose Psychose und Sucht mit Schwerpunkt bei Jungerwachsenen” befasst sich mit der Prävalenz und Erklärungsmodellen. Der zweite Teil gibt dann eine Übersicht zu Verlauf und psychosozialen Behandlungsmöglichkeiten.
Abstract
Epidemiological studies suggest that 20 % to 50 % of patients with schizophrenia have a lifetime comorbid substance use disorder (SUD). In first-episode psychosis this prevalence is even higher and varies between 20 % and 75 % with cannabis being the most widely used illicit drug. These difficult to treat patients usually have a worse prognosis as compared with non-substance abusing schizophrenic patients. Despite multiple theories proposed such as the self medication hypothesis, common or bidirectional factor models or genetic vulnerability, there is no consensus on the aetiology of increased rates of substance use in people with psychosis which is important to treat these patients. The dually diagnosed population is a heterogeneous group and it is likely that different models may explain comorbidity in different subgroups. The present review part one gives an overview on prevalence and explanation models for dual diagnosis psychosis and substance use with focus in adolescent and young adult populations, the second part reviews the clinical course for both disorders and current psychosocial treatment options.
Schlüsselwörter
Doppeldiagnose - Psychose - Sucht - Epidemiologie - Erklärungsmodelle
Key words
dual diagnosis - psychosis - substance abuse disorder - epidemiology - etiological theories
Literatur
1
Buckley P F.
Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.
Journal of Clinical Psychiatry.
2006;
67
5-9
2
Drake R E.
Dual diagnosis.
Psychiatry.
2007;
6
381-384
3
Tiet Q Q, Mausbach B.
Treatments for patients with dual diagnosis: a review.
Alcoholism: Clinical and Experimental Research.
2007;
31
513-536
4 Weltgesundheitsorganisation .Internationale Klassifikation psychischer Störungen: ICD 10, Kapitel V (F); klinisch-diagnostische Leitlinien. Bern; Huber 2000 4th
5 American Psychiatric Association .Diagnostisches und Statistisches Manual Psychischer Störungen – Textrevision- DSM-IV-TR. Göttingen; Hogrefe 2003
6
Martin C S, Winters K C.
Diagnosis and assessment of alcohol use disorders among adolescents.
Alcohol Health and Research World.
1998;
22
95-105
7
Chambers R A, Krystal J H, Self D W.
A neurobiological basis for substance abuse comorbidity in schizophrenia.
Biological Psychiatry.
2001;
50
71-83
8
Lambert M, Conus P, Lubman D I. et al .
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.
Acta Psychiatrica Scandinavica.
2005;
112
141-148
9
Hickman M, Vickerman P, Macleod J. et al .
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales.
Addiction.
2007;
102
597-606
10
Larsen T K, Melle I, Auestad B. et al .
Substance abuse in first-episode non-affective psychosis.
Schizophrenia Research.
2006;
88
55-62
11
Ajdacic-Gross V, Lauber C, Warnke I. et al .
Changing incidence of psychotic disorders among the young in Zurich.
Schizophrenia Research.
2007;
95
9-18
12
Verdoux H, Tournier M, Cougnard A.
Impact of substance use on the onset and course of early psychosis.
Schizophrenia Research.
2005;
79
69-75
13
Rehm J, Room R, Brink W. et al .
Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology.
European Neuropsychopharmacology.
2005;
15
389-397
14
Westermeyer J.
Comorbid schizophrenia and substance abuse: a review of epidemiology and course.
American Journal on Addictions.
2006;
15
345 s-355
15 Pfeiffer-Gerschel T, Kipke I, Lang P. et al .Bericht 2008 des nationalen REITOX-Knotenpunkts an die EBDD. Deutschland: Neue Entwicklungen, Trends und Hintergrundinformationen zu Schwerpunktthemen. Drogensituation 2007 / 2008. München; DBDD 2008
16 Europäische Beobachtungsstelle für Drogen und Drogensucht (EBDD) .Jahresbericht 2008: Stand der Drogenproblematik in Europa. Luxemburg; Amt für amtliche Veröffentlichungen der Europäischen Gemeinschaften 2008: 1-111
17
Kraus L, Augustin R, Orth B.
Illegale Drogen, Einstiegsalter und Trends. Ergebnisse des Epidemiologischen Suchtsurvey 2003.
Sucht.
2005;
51
19-28
18
Perkonigg A, Lieb R, Höfler M. et al .
Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents.
Addiction.
1999;
94
1663-1678
19
Sydow von K, Lieb R, Pfister H. et al .
The natural course of cannabis use, abuse and dependence over 4 years: a longitudinal community study of adolescents and young adults.
Drug and Alcohol Dependence.
2001;
64
347-361
20 Töppich J. Cannabiskonsum von Jugendlichen. In, Jugendkult Cannabis – Risiken und Hilfen. Berlin; Die Drogenbeauftragte der Bundesregierung 2005: 15-19
21
Bonnet U, Harries-Hedder K, Leweke F M. et al .
AWMF-Leitlinie: Cannabis-bezogene Störungen.
Fortschr Neurol Psychiatr.
2004;
72
318-329
22
Thomasius R, Stolle M.
Diagnostik und Behandlung psychischer Störungen durch Cannabiskonsum.
Psychiatrie und Psychotherapie up2date 2.
2008;
2
225-239
23
Sonntag D, Bauer C, Hellwich A K.
Deutsche Suchthilfestatistik 2005 für ambulante Suchteinrichtungen.
Sucht.
2006;
52
7-43
24 Bundeszentrale für gesundheitliche Aufklärung (BZgA) .Cannabiskonsum der Jugendlichen und jungen Erwachsenen in Deutschland. Ergebnisse der Repräsentativbefragung der Bundeszentrale für gesundheitliche Aufklärung. Köln; BZgA 2007
25 Die Drogenbeauftragte der Bundesregierung .Drogen- und Suchtbericht Mai 2008. Berlin; 2008
26 Bundeszentrale für gesundheitliche Aufklärung (BZgA) .Alkoholkonsum der Jugendlichen in Deutschland 2004 – 2007. Ergebnisse der Repräsentativbefragung der Bundeszentrale für gesundheitliche Aufklärung. Köln; BZgA 2007
27
Rabinowitz J, Bromet E J, Lavelle J. et al .
Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients.
Psychological Medicine.
1998;
28
1411-1419
28
Green B, Young R, Kavanagh D J.
Cannabis use and misuse prevalence among people with psychosis.
British Journal of Psychiatry.
2005;
187
306-313
29
Blanchard J J, Brown S A, Horan W P. et al .
Substance use disorders in schizophrenia: review, integration, and a proposed model.
Clinical Psychology Review.
2000;
20
207-234
30
Kraemer H C, Wilson K A, Hayward C.
Lifetime prevalence and pseudocomorbidity in psychiatric research.
Archives of General Psychiatry.
2006;
63
604-608
31
Regier D A, Farmer M E, Rae D S. et al .
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.
Journal of the American Medical Association.
1990;
264
2511-2518
32
Jacobsen L K, Southwick S M, Kosten T R.
Substance use disorders in patients with posttraumatic stress disorder: a review of the literature.
American Journal of Psychiatry.
2001;
158
1184-1190
33
Kalbag A S, Levin F R.
Adult ADHD and substance abuse: diagnostic and treatment issues.
Substance Use & Misuse.
2005;
40
1955-1958
34
Duke P J, Pantelis C, McPhillips M A.
Comorbid non-alcohol substance misuse among people with schizophrenia.
British Journal of Psychiatry.
2001;
179
509-513
35
Lammertink M, Löhrer F, Kaiser R.
Differences in substance abuse patterns: multiple drug abuse alone versus schizophrenia with multiple drug abuse.
Acta Psychiatrica Scandinavica.
2001;
104
361-366
36
Linszen D H, Dingemans P M, Lenior M E.
Cannabis use and the course of recent onset schizophrenic disorders.
Archives of General Psychiatry.
1994;
51
273-279
37
Wade D, Harrigan S, Edwards J. et al .
Course of substance misuse and daily tobacco use in first-episode psychosis.
Schizophrenia Research.
2006;
81
145-150
38
Kavanagh D J, Waghorn G, Jenner L. et al .
Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample.
Schizophrenia Research.
2004;
66
115-124
39
Wobrock T, Pajonk F G, D’Amelio R. et al .
Schizophrenie und Sucht.
psychoneuro.
2005;
31
433-440
40
Gouzoulis-Mayfrank E.
Doppeldiagnose Psychose und Sucht – Grundlagen und Therapie.
Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie.
2008;
36
245-253
41 Gouzoulis-Mayfrank E. Komorbidität Psychose und Sucht: Grundlagen und Praxis. Steinkopff Verlag 2007
42
Tiet Q Q, Finney J W, Moos R H.
Screening psychiatric patients for illicit drug use disorders and problems.
Clinical Psychology Review.
2008;
28
578-591
43
Drake R E, Wallach M A, McGovern M P.
Future directions in preventing relapse to substance abuse among clients with severe mental illnesses.
Psychiatric Services.
2005;
56
1297-1302
44
Cutler D L, Bevilacqua J, McFarland B H.
Four decades of community mental health: a symphony in four movements.
Community Mental Health Journal.
2003;
39
381-398
45
Drake R E, Green A I, Mueser K T.
The history of community mental health treatment and rehabilitation for persons with severe mental illness.
Community Mental Health Journal.
2003;
39
427-440
46
Mueser K T, Drake R E, Wallach M A.
Dual diagnosis: a review of etiological theories.
Addictive Behaviors.
1998;
23
717-734
47
Gregg D, Barrowclough C, Haddock G.
Reasons for increased substance use in psychosis.
Clinical Psychology Review.
2007;
27
494-510
48
Khantzian E J.
The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.
Harvard Review of Psychiatry.
1997;
4
231-244
49
Schneier F R, Siris S G.
A review of psychoactive substance use and abuse in schizophrenia.
Journal of Nervous and Mental Disease.
1987;
175
641-652
50
Dixon L, Haas G H, Weiden P J. et al .
Drug abuse in schizophrenic patients: clinical correlates and reasons for use.
American Journal of Psychiatry.
1991;
148
224-230
51
Pencer A, Addington J.
Reasons for using substances in adolescents with and without psychosis.
Early Intervention in Psychiatry.
2008;
2
42-44
52
Addington J, Duchak V.
Reasons for substance use in schizophrenia.
Acta Psychiatrica Scandinavica.
1997;
96
233-329
53
Spencer C, Castle D, Michie P T.
Motivations that maintain substance use among individuals with psychotic disorders.
Schizophrenia Bulletin.
2002;
28
233-247
54
Cantwell R, Brewin J, Glazebrook C. et al .
Prevalence of substance misuse in first-episode psychosis.
British Journal of Psychiatry.
1999;
174
150-153
55
Hambrecht M, Häfner H.
Substance abuse and the onset of schizophrenia.
Biological Psychiatry.
1996;
40
1155-1163
56
Bersani G, Orlandi V, Kotzalidis G D. et al .
Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.
European Archives of Psychiatry and Clinical Neuroscience.
2002;
252
86-92
57
Canton-Graae E, Nordstrom L G, McNeil T F.
Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.
Schizophrenia Research.
2001;
48
69-82
58
Barnett J H, Werners U, Secher S M. et al .
Substance use in a population-based clinic sample of people with first-episode psychosis.
British Journal of Psychiatry.
2007;
190
515-520
59
Drake R E, Wallach M A, Alverson H S. et al .
Psychosocial aspects of substance abuse by clients with severe mental illness.
Journal of Nervous and Mental Disease.
2002;
190
100-106
60
Drake R E, Mueser K T.
Co-occuring alcohol use disorder and schizophrenia.
Alcohol Research and Health.
2002;
26
99-102
61
Drake R E, Wallach M A.
Moderate drinking among people with severe mental illness.
Hospital and Community Psychiatry.
1993;
44
780-782
62
Swofford C D, Kasckow J W, Scheller-Gilkey G.
Substance use: a powerful predictor of relapse in schizophrenia.
Schizophrenia Research.
1996;
20
145-151
63
Gonzalez V M, Bradizza C M, Vincent P C. et al .
Do individuals with a severe mental illness experience greater alcohol and drug-related problems? A test of the supersensitivity hypothesis.
Addictive Behaviors.
2007;
32
477-490
64
Phillips P, Johnson S.
How does drug and alcohol misuse develop among people with psychotic illness? A literature review.
Social Psychiatry and Psychiatric Epidemiology.
2001;
36
269-276
65
O’Daly O G, Guillin O, Tsapakis E. et al .
Schizophrenia and substance abuse comorbidity: a role for dopamine sensitization?.
Journal of Dual Diagnosis.
2005;
1
11-40
66
Rounsaville B J.
DSM-V research agenda: substance abuse/psychosis comorbidity.
Schizophrenia Bulletin.
2007;
33
947-952
67
Thornicroft G, Meadows G, Politi P.
Is „cannabis psychosis” a distinct category?.
European Psychiatry.
1992;
7
277-282
68
Arendt M, Rosenberg R, Foldager L. et al .
Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.
British Journal of Psychiatry.
2005;
187
510-515
69
Arendt M, Preben B M, Rosenberg R. et al .
Familial predisposition for psychiatric disorder comparison of subjects treated for cannabis-induced psychosis and schizophrenia.
Archives of General Psychiatry.
2008;
65
1269-1274
70
Boydell J, Dean K, Dutta R. et al .
A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis.
Schizophrenia Research.
2007;
93
203-210
71
Caton C L, Hasin D S, Shrout P E. et al .
Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.
British Journal of Psychiatry.
2007;
190
105-111
72
Caton C L, Drake R E, Hasin D S.
Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.
Archives of General Psychiatry.
2005;
62
137-145
73
Leweke F M, Gerth C W, Klosterkotter J.
Cannabis-associated psychosis: current status of research.
CNS Drugs.
2004;
18
895-910
74
Fergusson D M, Poulton R, Smith P F. et al .
Cannabis and psychosis.
British Medical Journal.
2006;
332
172-175
75
Arseneault L, Cannon M, Witton J. et al .
Causal association between cannabis and psychosis: examination of the evidence.
British Journal of Psychiatry.
2004;
184
110-117
76
Henquet C, Murray R, Linszen D. et al .
The environment and schizophrenia: the role of cannabis use.
Schizophrenia Bulletin.
2005;
31
608-612
77
Henquet C, Di Forti M, Morrison P. et al .
Gene-environment interplay between cannabis and psychosis.
Schizophrenia Bulletin.
2008;
34
1111-1121
78
Andreasson S, Allebeck P, Engstrom A.
Cannabis and schizophrenia. A longitudinal study of swedish conscripts.
Lancet.
1987;
2
1483-1486
79
Zammit S, Allebeck P, Andreasson S. et al .
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.
British Medical Journal.
2002;
325
1199
80
Moore T, Zammit S, Lingford-Hughes A. et al .
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Lancet.
2007;
370
319-328
81
Webb E, Ashton C H, Kelly P. et al .
Alcohol and drug use in UK university students.
Lancet.
1996;
348
922-925
82
Arseneault L, Cannon M, Poulton R. et al .
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
British Medical Journal.
2002;
325
1212-1213
83
Lieb R, Isensee B, v. Sydow K. et al .
The Early Developmental Stages of Psychopathology Study (EDSP): a methodological update.
European Addiction Research.
2000;
6
170-182
84
DeWitt D J, Adlaf E M, Offord D R. et al .
Age at first alcohol use: a risk factor for the development of alcohol disorders.
American Journal of Psychiatry.
2000;
157
745-750
85
Chen C Y, Brian M S, Anthony J C.
Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000 – 2001.
Drug and Alcohol Dependence.
2005;
79
11-22
86
Rabinowitz J, Levine S Z, Häfner H.
A population based elaboration of the role of age of onset on the course of schizophrenia.
Schizophrenia Research.
2006;
88
96-101
87
Nimwegen van L, Haan de L, Beveren van N. et al .
Adolescence, schizophrenia and drug abuse: a window of vulnerability.
Acta Psychiatrica Scandinavica.
2005;
11
1-9
88
Pistis M, Perra S, Pillolla G. et al .
Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons.
Biological Psychiatry.
2004;
56
86-94
89
Solowij N, Michie P T.
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?.
Journal of Psychiatry and Neuroscience.
2007;
32
30-52
90
Stefanis N C, Delespaul P, Henquet C. et al .
Early adolescent cannabis exposure and positive and negative dimensions of psychosis.
Addiction.
2004;
99
1333-1341
91
Konings M, Henquet C, Maharajh H D. et al .
Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad.
Acta Psychiatrica Scandinavica.
2008;
118
209-213
92
Barnes T, Mutsatsa S, Hutton S. et al .
Comorbid substance use and age at onset of schizophrenia.
British Journal of Psychiatry.
2006;
188
237-242
93
Veen N D, Selten P J, Tweel van der I. et al .
Cannabis use and age at onset of schizophrenia.
American Journal of Psychiatry.
2004;
161
501-506
94
Mastrigt van S, Addington J, Addington D.
Substance misuse at presentation to an early psychosis program.
Social Psychiatry and Psychiatric Epidemiology.
2004;
39
69-72
95
Buhler B, Hambrecht M, Loffler W. et al .
Precipitation and determination of the onset and course of schizophrenia by substance abuse – a retrospective and prospective study of 232 population-based first illness episodes.
Schizophrenia Research.
2002;
54
243-251
96
Compton M T, Kelley M E, Ramsay C E. et al .
Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients.
Am J Psychiatry.
2009;
166
1251-1257
97
Semple D M, McIntosh A M, Lawrie S M.
Cannabis as a risk factor for psychosis: systematic review.
Journal of Psychopharmacology.
2005;
19
187-194
98
vanNimwegen L, Haan de L, Beveren van N. et al .
Adolescence, schizophrenia and drug abuse: a window of vulnerability.
Acta Psychiatr Scand.
2005;
11
1-9
99
Williams H J, Owen M J, O’Donovan M C.
Is COMT a susceptibility gene for schizophrenia?.
Schizophrenia Bulletin.
2007;
33
635-641
100
Collaborative Working Group on Clinical Trial Evaluations .
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders.
Journal of Clinical Psychiatry.
1998;
59
41-45
101
Zammit S, Spurlock G, Williams H. et al .
Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.
British Journal of Psychiatry.
2007;
191
402-407
102
Winkel van R, Hert de M, Vriendt de N. et al .
No comfirmation of gene-environment interaction between COMT VAL158 MET and adolescent-onset cannabis use in large sample of patients with schizophrenia.
Schizophrenia Research.
2008;
98
78-79
103
Kirkbride J, Fearon P, Morgan C. et al .
Heterogenity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study.
Archives of General Psychiatry.
2006;
63
250-258
104
Boydell J, Os O J, Caspi van A. et al .
Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999.
Psychological Medicine.
2006;
36
1441-1446
105
Os van J, Rutten B P, Poulton R.
Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions.
Schizophrenia Bulletin.
2008;
34
1066-1082
106
Winkel van R, Stefanis N C, Myin-Germeys I.
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction.
Schizophrenia Bulletin.
2008;
34
1095-1105
107
Degenhardt L, Hall W, Lynskey M.
Testing hypotheses about the relationship between cannabis use and psychosis.
Drug and Alcohol Dependence.
2003;
71
37-48
108
Mueser K T, Crocker A G, Frisman L B. et al .
Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders.
Schizophrenia Bulletin.
2006;
32
626-636
109
Mueser K T, Yarnold P R, Rosenberg S D.
Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups.
Schizophrenia Bulletin.
2000;
26
179-192
110
Hides L, Dawe S, Kavanagh D J. et al .
Psychotic symptom and cannabis relapse in recent-onset psychosis.
British Journal of Psychiatry.
2006;
189
137-143
111
Ferdinand R F, Sondeijker F, Ende van der J. et al .
Cannabis use predicts future psychotic symptoms, and vice versa.
Addiction.
2005;
100
612-618
PD Dr. Martin Lambert
Psychosen-Ersterkennungs- und Behandlungsprojekt (PEB) Klinik für Psychiatrie und Psychotherapie, Zentrum für Psychosoziale Medizin Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
eMail: lambert@uke.de